This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

OHIO (WJW) — After advising all vaccine providers in Ohio temporarily pause using the Johnson & Johnson vaccine after a recommendation by federal health officials, Gov. Mike DeWine held a press conference to discuss what that means for the state.

Tuesday, the Food and Drug Administration and the Centers for Disease Control advised pausing the use of the vaccine after an “extremely rare blood-clotting events of six people in the U.S. after receiving the vaccine.”

DeWine said today, that it is his understanding the pause is supposed to last “days to weeks.” Those locations that already have Johnson & Johnson vaccines are asked to hold on to them. The vaccines have mostly been given to colleges and universities as well as at mass vaccination sites, DeWine said.

Some sites are substituting Moderna and Pfizer vaccines for the Johnson & Johnson ones, while others are pausing for this week. DeWine said no decision has been made about the Wolstein Center in Cleveland at this time.

“Officials with the Ohio Department of Health are following this situation closely,” according to a press release from DeWine’s office.

According to the FDA, about seven million people in the United States have gotten the Johnson & Johnson vaccine.

Officials are reviewing data involving six cases of a rare and severe type of blood clot in six individuals after receiving the vaccine. All six were women, between the ages of 18 and 48. One of the women died.

The CDC will meet Wednesday to further review the cases. The FDA will review that analysis.

“Until that process is complete, we are recommending this pause,” according to the FDA. “This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot.”